Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Lam CSP, Ramasundarahettige C, Branch KRH et al (2022) Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O Trial
00169-7/asset/f395b8d2-b0e6-42b4-831a-894abf3af961/main.assets/gr1_lrg.jpg)
An independent affiliate publisher produced this content and may earn a commission if readers enroll through links here, at no added cost to you
Nausea hit 45% of participants
Optimal Candidates Patients with BMI 30 or higher without contraindications represent the core target population
US$ 21.20
US$ 29.81
US$ 27.92
US$ 29.56
